| Mild | Moderate | Severe | P- value |
---|---|---|---|---|
Baseline assessment | N = 48 | N = 62 | N = 94 | Â |
Demography | Â | Â | Â | Â |
 Female (n, %) | 35 (72.9%) | 47 (75.8%) | 71 (75.5%) | 0.752 |
 Age (years, IQR) | 40 (27–49) | 35 (27–46) | 37 (24–48) | 0.271 |
 Disease duration (months, IQR) | 24 (2–96) | 34 (6–96) | 24 (3–102) | 0.513 |
Clinical manifestation (n, %) | Â | Â | Â | Â |
 Systemic symptoms (fever, weakness, etc.) | 19 (39.6%) | 24 (38.7%) | 34 (36.2%) | 0.924 |
 Neurological symptoms (headache, amaurosis, etc.) | 14 (29.2%) | 26 (41.9%) | 55 (58.5%) | 0.544 |
 Cardiovascular symptoms (chest distress/pain, etc.) | 9 (18.8%) | 16 (25.8%) | 32 (34.1%) | 0.273 |
Complications (n, %) | Â | Â | Â | Â |
 Renal insufficiency | 2 (4.2%) #, * | 5 (8.1%) | 11 (11.7%) | 0.048 |
 Heart failure | 4 (8.3%) | 7 (11.3%) | 13 (13.8%) | 0.701 |
 Cerebral infarction | 2 (4.2%) | 2 (3.2%) | 5 (5.3%) | 0.821 |
Artery involvement (n, %) | Â | Â | Â | Â |
 Abdominal aorta | 20 (41.7%) | 32 (51.6%) | 53 (56.4%) | 0.293 |
 Renal artery | 20 (41.7%)* | 28 (45.2%)& | 68 (72.3%) | 0.043 |
 Thoracic aorta | 10 (20.8%) | 22 (35.5%) | 32 (34.1%) | 0.293 |
 Carotid artery | 13 (27.1%) | 26 (41.9%) | 39 (41.5%) | 0.115 |
 Subclavian artery | 27 (52.1%) | 33 (53.2%) | 47 (50.0%) | 0.744 |
Echocardiography (n, %) | Â | Â | Â | Â |
 Severe AR | 3 (6.3%) | 5 (8.1%) | 11 (11.7%) | 0.082 |
Follow-up assessment | N = 43 | N = 57 | N = 87 | Â |
Blood pressure control status (n, %) | Â | Â | Â | Â |
 Controlled | 26 (60.5%) | 32 (56.1%) | 37 (42.5%) | 0.082 |
 Improved | 15 (34.9%) | 22 (38.6%) | 39 (44.8%) | 0.727 |
 Failure | 2 (4.6%)* | 3 (5.3%)& | 11 (12.6%) | < 0.001 |
Events (n, %) | Â | Â | Â | Â |
 Persistent refractory or malignant hypertension | 3 (6.9%) #, * | 8 (14.0%) | 16 (18.4%) | 0.016 |
 Renal insufficiency | 2 (4.7%) | 4 (7.0%) | 6 (6.9%) | 0.322 |
 Congestive heart failure | 2 (4.7%) | 3 (5.3%) | 2 (2.3%) | 0.069 |
Events free survival by the end | 81.4%* | 70.2% | 59.8% | 0.047 |